Sign Up for Free!

Continue Analyzing the page and more.

Continue with Google

Already have an Account? Log In

The Trial has ended

Continue Analyzing the page and more.

Upgrade to Pro
Home Daily Intelligence Tracker
    • Plans Blog Contact
    Entera Bio Ltd logo
    ENTX

    Entera Bio Ltd

    MaveScore 10 Low model confidence
    Last Price US$1.21 As of Jun 15, 2026
    Market Cap US$57.8m Company size context
    7D Performance 1.68% Past 7 days
    1Y Performance -34.59% Past 12 months
    Model Rating
    Historical model output for research review

    Fundamental data date

    Mar 31, 2026

    77 days old

    Market price date

    Jun 15, 2026

    1 day old

    Coverage

    16/16

    No missing model inputs

    Data quality

    Excellent

    Current stored snapshot

    Transparent research score

    Why the model scores this stock

    MaveScore is a research prioritization score from 0 to 100. It is historical model output for watchlist review, not personalized financial advice.

    MaveScore 10 Low confidence

    Stored data quality

    Freshness and coverage checks

    Latest stored fundamentals and price inputs are recent enough for normal research review.

    16/16 Current stored snapshot

    Quality

    Quality score blends the latest weighted model rank with underlying profitability and dilution ranks.

    2/35 Weak

    Financial Strength

    Financial strength rewards durable profitability, margins, and positive free cash flow.

    6/25 Weak

    Valuation Support

    Valuation favors positive earnings, positive cash flow, and lower price-to-book multiples.

    1/15 Weak

    Momentum

    Momentum highlights research candidates with supportive 3-month and 6-month price regimes.

    1/15 Weak

    Shareholder Alignment

    Shareholder alignment rewards less dilutive share behavior and enough size for liquid research coverage.

    0/10 Weak

    Positive model output

    More live company inputs are needed before positive research signals can be surfaced.

    Research risks to review

    • Quality score blends the latest weighted model rank with underlying profitability and dilution ranks.
    • Financial strength rewards durable profitability, margins, and positive free cash flow.
    • Valuation favors positive earnings, positive cash flow, and lower price-to-book multiples.

    MaveScore uses historical model inputs, stored company fundamentals, and stored price context for research support only. Review missing inputs and business-specific risks before acting.

    Overview Price History News Competitors Earnings per Share Return on Equity Net Margin Share Buyback Leverage Financial Ratio
    Dashboard Funda..tals Deep..lue Prediction Screener Map

    Entera Bio Ltd Overview

    Industry: Biotechnology

    Sector: Healthcare

    Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of non-union fractures. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.

    Entera Bio Ltd is evaluated using Mavefund's quality framework: growing earnings, durable profit margins, conservative leverage, strong return on equity, and disciplined share repurchases.

    Score

    Price History & Performance

    Review Entera Bio Ltd in context before unlocking the interactive price chart, financial overlays, and downloadable ratio tables.

    Recent News



    News Image
    Entera Bio Ltd. (ENTX) Reports Q1 Loss, Misses Revenue Estimates
    Yesterday
    News Image
    New Strong Sell Stocks for August 19th
    3 days ago
    News Image
    Are Medical Stocks Lagging Arbutus Biopharma (ABUS) This Year?
    6 days ago

    Entera Bio Ltd Competitors

    Entera Bio Ltd operates in the Biotechnology industry within the Healthcare sector. Unlock the full page to compare peer rankings, valuation quality, profitability, leverage, and growth trends.

    Earnings Per Share

    EPS quality is one of the core Mavefund signals. Sign up to continue into the detailed EPS, ROE, margin, share buyback, leverage, and financial ratio analysis.

    Continue the analysis

    Sign up to unlock ROE, net margin, share buyback, leverage, financial ratios, peer charts, and downloads.

    View plans
    Ticker Image

    Entera Bio Ltd

    US$1.21

    US$57.8m

    1.68%

    -34.59%